US biotechnology company
US biotechnology company
Pelacarsen reduced lipoprotein(a) (Lp(a)) by 78% in a Phase III trial of more than 8,300 adults yet produced no reduction in major adverse cardiovascular events, raising questions about whether lowering …
Phase III DeLLphi-305 data show tarlatamab plus durvalumab extended median overall survival to 21.1 months versus 12.7 months with durvalumab alone in extensive-stage small cell lung cancer maintenance.
You must be logged in to post a comment.